Effect of nonalcoholic steatohepatitis on renal filtration and secretion of Adefovir (cas 106941-25-7)

Add time:08/08/2019    Source:sciencedirect.com

Background and aimsAdefovir, an acyclic nucleotide reverse transcriptase inhibitor used to treat hepatitis B viral infection, is primarily eliminated renally through cooperation of glomerular filtration with active tubular transport. Nonalcoholic steatohepatitis is a variable in drug disposition, yet the impact on renal transport processes has yet to be fully understood. The goal of this study was to determine the effect of nonalcoholic steatohepatitis on the pharmacokinetics of adefovir in rats given a control or methionine and choline deficient diet to induce nonalcoholic steatohepatitis.

We also recommend Trading Suppliers and Manufacturers of Adefovir (cas 106941-25-7). Pls Click Website Link as below: cas 106941-25-7 suppliers

Prev:Synthesis, pharmacological evaluation, and mechanistic study of Adefovir (cas 106941-25-7) mixed phosphonate derivatives bearing cholic acid and l
Next:Adefovir (cas 106941-25-7) dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction)